Dec. 4 at 4:09 PM
$IMMX IMMX may have just delivered its biggest moment yet. ASH 2025 data reportedly shows a 95 percent deep response rate in 19 out of 20 patients, up from 70 percent at ASCO, even after doubling the sample size. All responders reached dFLC below 1 mg/dL, a key marker linked to organ recovery and long term survival. This level of consistency and potency in relapsed AL amyloidosis, a disease with zero approved treatments, is extremely rare in CAR T. If confirmed, it significantly de risks NXC 201, strengthens the BLA path, and puts IMMX into true moonshot territory.
